Treating urinary tract infections in the era of antibiotic resistance

References

• Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198–1208. doi: 10.1056/NEJMoa1306801
   PubMed Web of Science ®Google Scholar
• Smith HS, Hughes JP, Hooton T, et al. Antecedent antimicrobial use increases the risk of uncomplicated cystitis in young women. Clin Infect Dis. 1997;25(1):63–68. doi: 10.1086/514502
   PubMed Web of Science ®Google Scholar
• Nielsen KL, Dynesen P, Larsen P, et al. Faecal Escherichia coli from patients with E coli urinary tract infection and healthy controls who have never had a urinary tract infection. J Med Microbiol. 2014;63(4):582–589. doi: 10.1099/jmm.0.068783-0
   PubMedGoogle Scholar
• Pérez-Galera S, Bravo-Ferrer JM, Paniagua M, et al. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control study (EURECA). eClinicalmedicine. 2023;57:101871. doi: 10.1016/j.eclinm.2023.101871
   PubMedGoogle Scholar
• Flores-Moreno K, López-Vidal Y, Ponce de León-Rosales S. Limited therapeutic options in Mexico for the treatment of urinary tract infections. Antibiotics. 2022;11(11):1656. doi: 10.3390/antibiotics11111656
   Google Scholar
• Ny S, Edquist P, Dumpis U, et al. Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia. J Glob Antimicrob Resist. 2019;17:25–34. doi: 10.1016/j.jgar.2018.11.004
   PubMed Web of Science ®Google Scholar
• Martinez P, Garzón D, Mattar S. CTX-M-producing Escherichia coli and Klebsiella pneumoniae isolated from community-acquired urinary tract infections in Valledupar, Colombia. Braz J Infect Dis. 2012;16(5):420–425. doi: 10.1016/j.bjid.2012.05.001
   PubMed Web of Science ®Google Scholar
• Castillo-Tokumori F, Irey-Salgado C, Malaga G. Worrisome high frequency of extended-spectrum beta-lactamase-producing Escherichia coli in community-acquired urinary tract infections: a case–control study. Int J Infect Dis. 2017;55:16–19. doi: 10.1016/j.ijid.2016.12.007
   PubMed Web of Science ®Google Scholar
• Islam MA, Islam MR, Khan R, et al. Prevalence, etiology and antibiotic resistance patterns of community-acquired urinary tract infections in Dhaka Bangladesh. PLoS ONE. 2022;17(9):e0274423. doi: 10.1371/journal.pone.0274423
   PubMed Web of Science ®Google Scholar
• Baran C, Küçükcan A. Antimicrobial susceptibility of bacteria isolated from urine cultures in southern Turkey. Curr Urol. 2022;16(3):180–184. doi: 10.1097/CU9.0000000000000144
   PubMedGoogle Scholar
• Radera S, Srivastava S, Agarwal J. Virulence genotyping and multidrug resistance pattern of Escherichia coli isolated from community-acquired and hospital-acquired urinary tract infections. Cureus. 2022;14(9):e29404. doi: 10.7759/cureus.29404
   PubMedGoogle Scholar
• Theuretzbacher U, Bush K, Harbarth S, et al. Critical analysis of antibacterial agents in clinical development. Nat Rev Microbiol. 2020;18(5):286–298. doi: 10.1038/s41579-020-0340-0
   PubMed Web of Science ®Google Scholar
• Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2017;129(2):242–258. doi: 10.1080/00325481.2017.1246055
   PubMed Web of Science ®Google Scholar
• Zollner-Schwetz I, König E. Treatment options for multidrug-resistant Gram-negatives in urinary tract infections. Curr Opin Urol. 2023;33(3):173–179. doi: 10.1097/MOU.0000000000001084
   PubMed Web of Science ®Google Scholar
• Falagas ME, Lourida P, Poulikakos P, et al. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58(2):654–663. doi: 10.1128/AAC.01222-13
   PubMed Web of Science ®Google Scholar
• Frimodt-Møller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents. 2002;19(6):546–553. doi: 10.1016/s0924-8579(02)00105-x
   PubMed Web of Science ®Google Scholar
• Leihof RF, Nielsen KL, Frimodt-Møller N. Asymptomatic bacteriuria (ABU) in elderly: prevalence, virulence, phylogeny, antibiotic resistance and complement C3 in urine. Microorganisms. 2021 14;9(2):390–401. doi: 10.3390/microorganisms9020390
   PubMed Web of Science ®Google Scholar
• Bilsen MP, Jongeneel RMH, Schneeberger C, et al. Definitions of urinary tract infection in Current research: a systematic review. Open Forum Infect Dis. 2023 Jun 27;10(7):332. PMID: 37426954; PMCID: PMC10323732. 10.1093/ofid/ofad332.
   Web of Science ®Google Scholar
• Little P, Turner S, Rumsby K, et al. Dipsticks and diagnostic algorithms in urinary tract infection: development and validation, randomised trial, economic analysis, observational cohort and qualitative study. Health Technol Assess. 2009;13(19):iii‐iv, ix‐xi, 1‐73. doi: 10.3310/hta13190
   Web of Science ®Google Scholar
• Knottnerus BJ, Geerlings SE, van Charante EP M, et al. Toward a simple diagnostic index for acute uncomplicated urinary tract infections. Ann Fam Med. 2013;11:442–451. 24019276. doi: 10.1370/afm.1513.
   PubMed Web of Science ®Google Scholar
• Beyer AK, Cordoba GC, Holm A. Validity of microscopy for diagnosing urinary tract infection in general practice. A systematic review. Scand J Primary Health Care. 2019;37:373–379. doi: 10.1080/02813432.2019.1639935
   PubMed Web of Science ®Google Scholar
• Ferry S, Burman LG, Holm SE. Uricult® and Sensicult® dipslides for diagnosis of bacteriuria and prediction of drug resistance in primary health care. Scand J Primary Health Care. 1989;7:123–128. doi: 10.3109/02813438909088659
   PubMedGoogle Scholar
• Bongard E, Frimodt-Møller N, Gal M, et al. Analytic laboratory performance of a point of care urine culture kit for diagnosis and antibiotic susceptibility testing. Eur J Clin Microbiol Infect Dis. 2015;34(10):2111–2119. doi: 10.1007/s10096-015-2460-4
   PubMed Web of Science ®Google Scholar
• https://www.nice.org.uk/guidance/hte7/chapter/1-Recommendations
   Google Scholar
• Lezzi P, Cappelini F, Intra J, et al. The diagnostic performances of the Atellica 1500 automated urinanalysis system for ruling out bacterial urinary tract infection. Clinica Chimica Acta. 2023;548:117494. doi: 10.1016/j.cca.2023.117494
   PubMed Web of Science ®Google Scholar
• Wolfe AJ, Toh E, Shibata N, et al. Evidence of uncultivated bacteria in the adult female bladder. J Clin Microbiol. 2012;50(4):1376–1383. doi: 10.1128/JCM.05852-11
   PubMed Web of Science ®Google Scholar
• Dong Q, Nelson DE, Toh E, et al. The microbial communities in male first catch urine are highly similar to those in paired urethral swab specimens. PLoS One. 2011;6(5):e19709. doi: 10.1371/journal.pone.0019709
   PubMed Web of Science ®Google Scholar
• Christensen JJ, Korner B, Kjaergaard H. Aerococcus-like organisms-an unnoticed urinary tract pathogen. APMIS. 1989;97(6):539–546. doi: 10.1111/j.1699-0463.1989.tb00828.x
   PubMed Web of Science ®Google Scholar
• Nielsen HL, Søby KM, Christensen JJ, et al. Actinobaculum schaalii: A common cause of urinary tract infection in the elderly population. Bacteriol Clinical Characteristics, Scand J Infect Dis. 2010;42(1):43–47. doi: 10.3109/00365540903289662
   Google Scholar
• Ferry SA, Holm SE, Stenlund H, et al. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo- controlled study. Scand J Infect Dis. 2004;36(4):296–301. doi: 10.1080/00365540410019642
   PubMed Web of Science ®Google Scholar
• Gágyor I, Bleidorn J, Kochen MG, et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomized controlled trial. Brit Med J. 2015;351:h6544. doi: 10.1136/bmj.h6544
   PubMed Web of Science ®Google Scholar
• Vik I, Bollestad M, Grude N, et al. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women—A double-blind, randomized non-inferiority trial. PLOS Med. 2018;15(5):e1002569. doi: 10.1371/journal.pmed.1002569
   PubMed Web of Science ®Google Scholar
• Bjerrum L, Lindbæk M. Which treatment strategy for women with symptoms of urinarytract infection? BMJ. 2015;351. doi: 10.1136/bmj.h6888
   Google Scholar
• Jansåker F, Li X, Vik I, et al. The risk of pyelonephritis following uncomplicated cystitis: a nationwide primary healthcare study. Antibiotics. 2022;11(12):1695. doi: 10.3390/antibiotics11121695
   Google Scholar
• Rousseau M, Mariano LL, Canton T, et al. Tissue-resident memory T cells mediate mucosal immunity to recurrent urinary tract infection. Sci Immunol. 2023;8(83):eabn4332. doi: 10.1126/sciimmunol.abn4332
   PubMed Web of Science ®Google Scholar
• Sihra N, Goodman A, Zakri R, et al. Nonantibiotic prevention and management of recurrent urinary tract infection. Nature Rev Urol. 2018;15(12):750–776. doi: 10.1038/s41585-018-0106-x
   PubMed Web of Science ®Google Scholar
• Narayan Swamy SN, Jakanur RK, Sangeetha SR. Significance of C-reactive protein levels in categorizing upper and lower urinary tract infection in adult patients. Cureus. 2022;14(6):e26432. doi: 10.7759/cureus.26432
   PubMed Web of Science ®Google Scholar
• Malmros K, Huttner BD, McNulty C, et al. Comparison of antibiotic treatment guidelines for urinary tract infections in 15 European countries: results of an online survey. Int J Antimicrob Agents. 2019;54(4):478–486. doi: 10.1016/j.ijantimicag.2019.06.015
   PubMed Web of Science ®Google Scholar
• Stewart AG, Bauer MJ, Butkiewicz D, et al. In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial. Internat J Antimicrob Ag. 2023;62:106858. doi: 10.1016/j.ijantimicag.2023.106858
   PubMed Web of Science ®Google Scholar
• Cuevas O, Cercenado E, Gimeno M, et al. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study. Diagn Microbiol Infect Dis. 2010;67(3):251–260. doi: 10.1016/j.diagmicrobio.2010.02.013
   PubMed Web of Science ®Google Scholar
• Mendes RE, Arends SJR, Streit JM, et al. Contemporary evaluation of tebipenem in vitro activity against Enterobacterales clinical isolates causing urinary tract infections in US medical Centers (2019–2020). Microbiol Spectr. 2023;11(1):e0205722. doi: 10.1128/spectrum.02057-22
   PubMed Web of Science ®Google Scholar
• WHO guidance AWaRe. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2022.02
   Google Scholar
• Huttner A, Verhaegh EM, Harbarth S, et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015;70(9):2456–2464. doi: 10.1093/jac/dkv147
   PubMed Web of Science ®Google Scholar
• Zykov IN, Samuelsen Ø, Jakobsen L, et al. Pharmacokinetics and pharmacodynamics of fosfomycin and it’s activity against extended-spectrum-βlactamase-, plasmid-mediated AmpC-, and carbapenemase-producing Escherichia coli in a murine urinary tract infection model. Antimicrob Agents Chemother. 2018;62(6):e02560–17. doi: 10.1128/AAC.02560-17
   PubMed Web of Science ®Google Scholar
• Fuchs F, Ahmadzada A, Plambeck L, et al. Susceptibility of clinical Enterobacterales isolates with common and rare carbapenemases to mecillinam. Front Microbiol. 2021;11:627267. doi: 10.3389/fmicb.2020.627267
   PubMed Web of Science ®Google Scholar
• Zykov IN, Frimodt-Møller N, Småbrekke L, et al. Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model. Int J Antimicrob Agents. 2020;55(2):105851. doi: 10.1016/j.ijantimicag.2019.11.008
   PubMed Web of Science ®Google Scholar
• Milano A, Sulejmani A, Intra J, et al. Antimicrobial resistance trends of Escherichia coli isolates from outpatient and inpatient urinary infections over a 20-year period. Microb Drug Resist. 2022;28(1):63–72. doi: 10.1089/mdr.2021.0010
   PubMed Web of Science ®Google Scholar
• Nilsson AI, Berg OG, Aspevall O, et al. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother. 2003;9:2850–2858. doi: 10.1128/AAC.47.9.2850-2858.2003
   Google Scholar
• Thulin E, Sundqvist M, Andersson DI. Amdinocillin (mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli. Antimicrob Agents Chemother. 2015;59(3):1718–1727. doi: 10.1128/AAC.04819-14
   PubMed Web of Science ®Google Scholar
• Frimodt-Møller N, Simonsen GS, Larsen AR, et al. Pivmecillinam, the paradigm of an antibiotic with low resistance rates in Escherichia coli urine isolates despite high consumption. J Antimicrob Chemother. 2022;78(1):289–295. doi: 10.1093/jac/dkac396
   PubMed Web of Science ®Google Scholar
• Konwar M, Gogtay NJ, Ravi R, et al. Evaluation of efficay and safety of fosfomycin versus nitrofurantoin for the treatment of uncomplicated lower urinary tract infection (UTI) in women – a systematic review and meta-analysis. J Chemother. 2022;34(3):139–148. doi: 10.1080/1120009X.2021.1938949
   PubMed Web of Science ®Google Scholar
• Jansåker F, Boel JB, Thønnings S, et al. Pivmecillinam compared to other antimicrobials for community-acquired urinary tract infections with Escherichia coli, ESBL-producing or not – a retrospective cohort study. Infect Drug Res. 2019;12:1691–1702. doi: 10.2147/IDR.S209255
   PubMed Web of Science ®Google Scholar